Member of Farmavita.Net offers EU CTD Dossier of  Olanzapine, tablets, 2.5/5/7.5/10/15/20 mg.

Dossier is ready, not submited.

Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.

Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C (Ki=4 and 11 nM, respectively), dopamine D1-4 (Ki=11-31 nM), muscarinic M1-5 (Ki=1.9-25 nM), histamine H1 (Ki=7 nM), and adrenergic a1 receptors (Ki=19 nM). Olanzapine binds weakly to GABAA, BZD, and b adrenergic receptors (Ki>10 mM).

The mechanism of action of olanzapine, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated through a combination of dopamine and serotonin type 2 (5HT2) antagonism. The mechanism of action of olanzapine in the treatment of acute manic episodes associated with BipolarI Disorder is unknown.

Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of olanzapine. Olanzapine’s antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects. Olanzapine’s antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Olanzapine’s antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.

More details http://www.rxlist.com/cgi/generic/olanzapine.htm 

Comments

Add New Search RSS

marius_ozone  - olanzapine interest   |Author |2007-10-25 09:53:24 We have an interest in evaluating Olanzapine for Romania, Poland, Bulgaria, Czech, Slovakia, Hungary and Ukraine. We will need dossier in CTD ready for submission for MRP or DCP and a supply contract for finish goods. Reply

Daniela Zelaschi   |Author |2008-03-31 19:52:16 WE are interested in the dossier for major EU contries without supply obligation Regards Daniela Reply

Write comment
Name:
Email:	do not notifynotify
Website:
Title:
	Please input the anti-spam code that you can read in the image.

Powered by !JoomlaComment 3.26

3.26 Copyright (C) 2008 Compojoom.com / Copyright (C) 2007 Alain Georgette / Copyright (C) 2006 Frantisek Hliva. All rights reserved."

• Therapeutic Vaccines (17/08/2010)
• Therapeutic Cancer Vaccines (07/05/2010)
• APA meeting 2009 (29/05/2009)

• Risedronate (31/12/2005)
• Quetiapine (31/12/2005)
• Pantoprazole (31/12/2005)

• Losartan (31/12/2005)
• Cyproter./ethinylestradiol (31/12/2005)
• Irbesartan (31/12/2005)
• Galantamine (31/12/2005)
• Esomeprazole (31/12/2005)
• Escitalopram (31/12/2005)
• Donepezil (31/12/2005)
• Candesartan (31/12/2005)
• Atorvastatin (31/12/2005)